Spotlight Reports2018-04-04T16:33:58+00:00

Report Spotlights

RealWorld Dynamix™: Biologic/Otezla Switching in Psoriasis US 2018 Spotlight

Efficacy is the most common trigger for a switch, though the switch patterns differ dramatically depending on whether it was a primary vs. secondary efficacy issue, with other factors, such as patient and payer influence, also playing a role. Reasons for new brand choice also vary between classes of treatment. View complimentary data highlights full 2018 report below.

November 28, 2018|

RealTime Dynamix™: Atopic Dermatitis US Q4 2018 Spotlight

After over a year and a half on the market, U.S. dermatologists (n=102) remain extremely pleased with Sanofi / Regeneron’s Dupixent. In Spherix’s fourth quarter update of RealTime Dynamix™: Atopic Dermatitis (US), collaborating dermatologists indicated that the first biologic to treat moderate-to-severe atopic dermatitis has consistently exceeded expectations, and satisfaction with the IL-4/13 inhibitor remains extremely high.

November 7, 2018|